(Q44611689)

4 December 2017

No effect of simvastatin treatment on insulin sensitivity in patients with primary hypercholesterolemia (English)

1 reference

4 December 2017

0 references

1 reference

Mustafa Kemal Balci

2

0 references

author name string

Hasan Altunbaş

series ordinal

1

1 reference

PubMed ID

14535628

4 December 2017

Umit Karayalçin

series ordinal

3

1 reference

4 December 2017

1 August 2003

1 reference

4 December 2017

1 reference

4 December 2017

29

1 reference

4 December 2017

3

1 reference

4 December 2017

265-275

1 reference

The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Harvard Atherosclerosis Reversibility Project Research Group

4 December 2017

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Statins do more than just lower cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Cardiovascular risk continuum: implications of insulin resistance and diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Inhibition of growth factor signaling pathways by lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Lovastatin Disrupts Early Events in Insulin Signaling: A Potential Mechanism of Lovastatins Anti-Mitogenic Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Lovastatin inhibits the stimulation of mitogen-activated protein kinase by insulin in HIRcB fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Activation of the Ras/mitogen-activated protein kinase signaling pathway alone is not sufficient to induce glucose uptake in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Differential requirement for p21ras activation in the metabolic signaling by insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Effect of a reduced-fat diet with or without pravastatin on glucose tolerance and insulin sensitivity in patients with primary hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Long-term effects of simvastatin in hypercholesterolemic patients with NIDDM and additional atherosclerotic risk factors. Hyogo Simvastatin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Effects of simvastatin versus gemfibrozil on lipids and glucose control in patients with non-insulin-dependent diabetes mellitus. NIDDM Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Improvement of glucose tolerance by bezafibrate in non-obese patients with hyperlipidemia and impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Lovastatin does not affect oral glucose tolerance in hypercholesterolemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Effect of pravastatin treatment on glucose, insulin, and lipoprotein metabolism in patients with hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Effects of fluvastatin treatment on insulin sensitivity in patients with hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Short-term safety and efficacy of low-dose simvastatin in elderly patients with hypertensive hypercholesterolemia and fasting hyperinsulinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Beneficial effects of pravastatin on fasting hyperinsulinemia in elderly hypertensive hypercholesterolemic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Mevalonate deprivation impairs IGF-I/insulin signaling in human vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Lack of effect of simvastatin on insulin sensitivity in Type 2 diabetic patients with hypercholesterolaemia: results from a double-blind, randomized, placebo-controlled crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120025034

21 January 2018

Identifiers

DOI

10.1081/ERC-120025034

1 reference

4 December 2017

1 reference

PubMed ID

14535628